Search for BAFF signaling inhibitors as novel drugs for the treatment of Sjogren's syndrome.
| Project/Area Number |
22591084
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAKEUCHI Tsutomu 慶應義塾大学, 医学部, 教授 (50179610)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 膠原病学 / サイトカイン / シェーグレン症候群 / BAFF / 細胞シグナル伝達 / 単球 / IL-6 / シグナル伝達 / JAK3 / 阻害剤 / リン酸化 / BAFF受容体 |
|---|
| Research Abstract |
Aiming at development of new disease-modifying drugs for Sjogren's syndrome (SS), we established an in vitro model for the screening of compounds that inhibit signal transduction triggered by a B cell activating factor, BAFF. This model enabled us to anal
|
Report
(4 results)
Research Products
(38 results)
